{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:59:43Z","timestamp":1780639183238,"version":"3.54.1"},"reference-count":25,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterized by impaired glycosaminoglycan degradation, leading to multisystem involvement and progressive growth impairment. Longitudinal growth data in MPS IVA and MPS IIIA, including the association of ERT with growth outcomes, remain limited. This study aimed to characterize growth trajectories in MPS IVA and MPS IIIA and to assess the association of ERT with Elosulfase alfa on growth outcomes in MPS IVA patients. Methods: We retrospectively analyzed growth data from 39 patients with MPS subtypes IIIA and IVA followed at a single center between 2004 and 2024. Height and weight standard deviation scores (SDS) were calculated relative to CDC growth references and modeled using linear mixed-effects models (LMM). In the MPS IVA subgroup, the effect of ERT with Elosulfase alfa was assessed using LMM and paired SDS comparisons. Results: Growth impairment was evident across both subtypes with distinct trajectories. MPS IIIA patients showed significant height decline after age six with progressive weight loss in later childhood. MPS IVA patients exhibited persistently severe short stature and a tendency toward overweight with advancing age. Among the 16 MPS IVA patients treated with Elosulfase alfa who were included in the analysis, height SDS declined significantly during treatment (\u22120.127 SDS\/year [95% CI: \u22120.194, \u22120.061], p &lt; 0.001), and the rate of decline was not significantly affected by age at ERT initiation (interaction p = 0.53). Conclusions: ERT with Elosulfase alfa did not prevent progressive height loss relative to population norms. The rate of height SDS decline was not significantly influenced by the timing of ERT initiation (interaction p = 0.53), and causal conclusions cannot be drawn from this observational data.<\/jats:p>","DOI":"10.3390\/jcm15114178","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:36:18Z","timestamp":1780076178000},"page":"4178","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Growth Patterns in MPS IVA and MPS IIIA: A Longitudinal Single-Center Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4551-5708","authenticated-orcid":false,"given":"Lior","family":"Carmon","sequence":"first","affiliation":[{"name":"Pediatrics Endocrinology Unit, Saban Children\u2019s Hospital, Soroka University Medical Center, Beer-Sheva 8410501, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Nassar","sequence":"additional","affiliation":[{"name":"Pediatrics Endocrinology Unit, Saban Children\u2019s Hospital, Soroka University Medical Center, Beer-Sheva 8410501, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna","family":"Idan","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar","family":"Leifman","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-8150","authenticated-orcid":false,"given":"David","family":"Shaki","sequence":"additional","affiliation":[{"name":"Pediatrics Endocrinology Unit, Saban Children\u2019s Hospital, Soroka University Medical Center, Beer-Sheva 8410501, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Elamour","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"},{"name":"Pediatric Ambulatory Center, Saban Children\u2019s Hospital, Soroka University Medical Center, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Hershkovitz","sequence":"additional","affiliation":[{"name":"Pediatrics Endocrinology Unit, Saban Children\u2019s Hospital, Soroka University Medical Center, Beer-Sheva 8410501, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Loewenthal","sequence":"additional","affiliation":[{"name":"Pediatrics Endocrinology Unit, Saban Children\u2019s Hospital, Soroka University Medical Center, Beer-Sheva 8410501, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0649-2603","authenticated-orcid":false,"given":"Alon","family":"Haim","sequence":"additional","affiliation":[{"name":"Pediatrics Endocrinology Unit, Saban Children\u2019s Hospital, Soroka University Medical Center, Beer-Sheva 8410501, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna Staretz","family":"Chacham","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"},{"name":"Rare Diseases Center, Saban Children\u2019s Hospital, Soroka University Medical Center, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13052-019-0691-1","article-title":"The use of recombinant human growth hormone in patients with mucopolysaccharidoses and growth hormone deficiency: A case series","volume":"45","author":"Cattoni","year":"2019","journal-title":"Ital. J. Pediatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2018.03.004","article-title":"Growth impairment in mucopolysaccharidoses","volume":"124","author":"Melbouci","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00431-019-03330-x","article-title":"Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: Expert opinion","volume":"178","author":"Guffon","year":"2019","journal-title":"Eur. J. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s13023-022-02486-4","article-title":"Comparison of growth dynamics in different types of MPS: An attempt to explain the causes","volume":"17","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"R\u00f3\u017cd\u017cy\u0144ska-\u015awi\u0105tkowska, A., Szklanny, K., Marucha, J., and Tylki-Szyma\u0144ska, A. (2020). Modeling Morquio A syndrome: An anthropometric study of body characteristics and stature. Diagnostics, 10.","DOI":"10.21203\/rs.2.20223\/v1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12519-014-0517-6","article-title":"Growth patterns in children with mucopolysaccharidosis I and II","volume":"11","author":"Jurecka","year":"2015","journal-title":"World J. Pediatr."},{"key":"ref_7","first-page":"25","article-title":"Growth patterns and the use of growth hormone in the mucopolysaccharidoses","volume":"3","author":"Polgreen","year":"2010","journal-title":"J. Pediatr. Rehabil. Med."},{"key":"ref_8","first-page":"1286","article-title":"Growth charts for patients affected with Morquio A disease","volume":"146","author":"Tomatsu","year":"2008","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2013.06.008","article-title":"Mucopolysaccharidosis IVA: Correlation between genotype, phenotype and keratan sulfate levels","volume":"110","author":"Tomatsu","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","article-title":"The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects","volume":"109","author":"Harmatz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13353-019-00491-1","article-title":"Novel data on growth phenotype and causative genotypes in 29 patients with Morquio (Morquio-Brailsford) syndrome from Central-Eastern Europe","volume":"60","author":"Kulpanovich","year":"2019","journal-title":"J. Appl. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ymgme.2015.11.013","article-title":"Bone mineral density in MPS IV A (Morquio syndrome type A)","volume":"117","author":"Kecskemethy","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2022.08.007","article-title":"Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfa","volume":"137","author":"Mitchell","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s10038-019-0604-6","article-title":"Effect of enzyme replacement therapy on the growth of patients with Morquio A","volume":"64","author":"Doherty","year":"2019","journal-title":"J. Hum. Genet."},{"key":"ref_15","first-page":"101189","article-title":"Long-term outcomes of enzyme replacement therapy from a large cohort of Korean patients with mucopolysaccharidosis IVA (Morquio A syndrome)","volume":"42","author":"Sung","year":"2025","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13023-022-02332-7","article-title":"Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries","volume":"17","author":"Magner","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Nakamura-Utsunomiya, A., Nakamae, T., Kagawa, R., Karakawa, S., Sakata, S., Sakura, F., Tani, C., Matsubara, Y., Ishino, T., and Tajima, G. (2020). A case report of a Japanese boy with Morquio A syndrome: Effects of enzyme replacement therapy initiated at the age of 24 months. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030989"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-021-01761-0","article-title":"Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: A case series","volume":"16","author":"Basaran","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/pr.2015.169","article-title":"Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y","volume":"78","author":"Jones","year":"2015","journal-title":"Pediatr. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Softw."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajmg.a.36833","article-title":"International guidelines for the management and treatment of Morquio A syndrome","volume":"167","author":"Hendriksz","year":"2015","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: Efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10545-013-9658-3","article-title":"Growth in patients with mucopolysaccharidosis type III (Sanfilippo disease)","volume":"37","author":"Broere","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Thomas, S., Ramaswami, U., Cleary, M., Yaqub, M., and Raebel, E.M. (2021). Gastrointestinal manifestations in mucopolysaccharidosis type III: Review of death certificates and the literature. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194445"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"102159","DOI":"10.1016\/j.jbc.2022.102159","article-title":"Impaired mitophagy in Sanfilippo A mice causes hypertriglyceridemia and brown adipose tissue activation","volume":"298","author":"Tillo","year":"2022","journal-title":"J. Biol. Chem."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4178\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:01:34Z","timestamp":1780635694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114178"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114178","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}